Jaymes Holland brings over 20 years of oncology clinical research and drug development experience in both pharmaceutical and biotech settings. He has contributed to the successful approvals of therapies such as Gleevec, Exjade, Tasigna, Avastin, Cabometyx, and Cometriq. His expertise spans Phases I–III with a focus on label-enabling clinical pharmacology studies, IND strategy, and regulatory execution. Jaymes has been recognized with industry awards at Novartis and Pfizer and is known for his scientific rigor, cross-functional leadership, and ability to navigate complex development challenges with precision and clarity.